Teva Pharmaceuticals announced on March 10, 2023, the FDA approval of its generic version of FDA-approved with its High Blood Pressure drugs (HBP) and epilepsy. This approval allows Teva to enter a lucrative market, further strengthening its generics portfolio amidst ongoing industry competitiveness.